On March 19th, Novo Nordisk announced an investment of approximately 4 billion yuan in Tianjin for the expansion project of sterile preparations, and held the groundbreaking ceremony for the expansion project.
In the first quarter of 2023, Novo Nordisk invested 1.18 billion yuan to launch a finished product workshop expansion project and introduce a pre filled injection pen production line. The aseptic formulation expansion project invested and constructed this time will adopt globally leading isolator technology to provide a higher level of aseptic guarantee for formulation production. The entire project is planned to be completed by 2027.
It is reported that 30 years ago, Novo Nordisk built a Tianjin production plant in Tianjin and made it one of its global strategic production bases. Arnold Johnson, Vice President of Global Enterprises and President of Tianjin Production Plant at Novo Nordisk, stated today that "Tianjin Production Plant is one of Novo Nordisk's strategic production bases globally and plays an important role in the global supply chain. Through this expansion, production capacity will be further increased, supporting the localization and production of more innovative drugs in the future, and providing high-quality drugs for patients." It is reported that 30 years ago, Novo Nordisk built a Tianjin Production Plant in Tianjin, making it one of its global strategic production bases.